Hannah Clarke

A real-world analysis found that achieving a PSA level below 0.2 ng/mL was associated with improved overall survival in mCSPC.

These FAQs highlight key recommendations and practical takeaways from the 2026 AUA/ASTRO Clinically Localized Prostate Cancer guideline amendment.

The phase 3 PSMAddition trial found that adding lutetium Lu 177 vipivotide tetraxetan to ADT and an ARPI significantly improved rPFS in mHSPC.

The registrational trial will compare ivonescimab plus enfortumab vedotin vs pembrolizumab plus enfortumab vedotin for locally advanced or metastatic urothelial carcinoma.

The next-generation implant is designed to extend the implant longevity from 10 years to 15 years.

A recap of the FDA submissions and regulatory decisions in urology from July 2026.

OMCAZIO demonstrated bioequivalence to CABOMETYX at a lower dose and was found to have no clinically significant food effect.

The approval is supported by data from the phase 3 PSMAddition trial.

A reference on the key recommendations from the AUA Testosterone Deficiency guideline.

AI in medicine is here. What happens next matters for the future of health care delivery.

A 10-year registry analysis found focal HIFU and cryotherapy achieved durable cancer control and low prostate cancer mortality in localized disease.

This FAQ outlines the major recommendations from PCWG4 for urologists and clinical investigators involved in prostate cancer clinical trials.

Phase 3 BOND-003 data published in The Lancet Oncology showed that intravesical cretostimogene grenadenorepvec produced durable complete responses and a favorable safety profile in patients with high-risk, BCG-unresponsive NMIBC with CIS.

Darlifarnib plus cabozantinib demonstrated encouraging antitumor activity with a manageable safety profile in patients with ccRCC, including both cabozantinib-naive and cabozantinib-exposed populations.

CAPTAIN trial data showed TULSA preserved penile length, continence, and erectile function compared with robotic prostatectomy in localized prostate cancer.

The PDUFA target action date is in the fourth quarter of 2026.

The study showed that perioperative EV–pembrolizumab improved EFS, OS, and pCR rate vs neoadjuvant cisplatin-gemcitabine in patients with MIBC who are eligible for cisplatin-based chemotherapy.

Olaparib's indications in the US include use as a single agent for patients with HRR gene-mutated mCRPC and in combination with abiraterone and prednisone for patients with BRCA-mutated mCRPC.

These results provided the basis for the ongoing randomized phase 3 ProstACT Global trial evaluating 177Lu-rosopatamab tetraxetan in mCRPC.

This marks the first phase 3 study of a targeted radiopharmaceutical therapy in clear cell renal cell carcinoma.

Results from a first-in-human phase 0 feasibility trial showed that combined bladder and kidney transplantation was technically feasible.

The Department of Defense will begin annual testosterone deficiency screening for service members aged 30 years and older.

The phase 2 study is assessing whether an adaptive treatment approach can improve responses and enable treatment pauses for select patients.

The pivotal phase 3 Himalayas-1 trial will evaluate rinzimetostat plus darolutamide vs with physician's choice of an ARPI or docetaxel.

According to the authors, the findings lay the groundwork for future work of genomics-guided treatment de-escalation in prostate cancer.

This decision extends the indication for pembrolizumab plus enfortumab vedotin to all patients with MIBC who are candidates for cystectomy.

The phase 1 trial is assessing the safety and preliminary antitumor activity of actinium (225Ac) rhPSMA-10.1 injection.

FDA clearance of the IND for UGN-501 paves the way for a first-in-human phase 1 trial evaluating its safety and feasibility in patients with NMIBC.

The findings suggest that a significant proportion of participants may benefit from discontinuing tamsulosin.

A recent meta-analysis suggests that the Prolaris combined clinical risk score is prognostic across NCCN risk groups in men with localized prostate cancer.